Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

armacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug product, AT2220 (1-deoxynojirimycin HCl), the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, and the timing of updates on the interactions with the FDA on the AT2220 program. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or un
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 Best Sanitizers, ... for an alcohol-based hand sanitizer, asks food processors and ... comparing the hand sanitizer they’re currently using to Best ... Hand hygiene is critical to fighting cross-contamination and the ... Best Sanitizers believes there are key criteria that make ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... -- Next month, executives from clinical trial marketing firm BBK Worldwide ... Patient-Centered Clinical Trials 2014 , to be held at ... September 4-5. Patient recruitment experts Bonnie A. Brescia , ... share insights on the benefits of employing an effective patient ... media to mobile apps – can be used to drive ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... cites Dr. Lanza for ,Courage Under Fire, ... (OTC Bulletin Board: ACTC) is proud to announced ... Research and Scientific,Development, has been recognized for his ... in the current issue of PharmaVOICE (cover,story July/August ...
... New USA Subsidiary Meets Demand for SLIM Search(TM) ... Aug. 21 Supporting the growing,demand for its ... Ltd. announces the opening of its new sales, ... Mission Viejo,California. SLIM Search, Inc. is the leading ...
... LOUIS, Aug. 20 The MattsonJack Group, Inc.,(MattsonJack), ... Dhawan M.D.,M.B.A., M.P.H. to Medical Director for MattsonJack. ... joined MattsonJack in September 2000 as a consultant ... M.B.A. from the,University of Missouri -- Kansas City. ...
Cached Biology Technology:Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3Cartesian Gridspeed Opens Subsidiary Operation in North America 2Cartesian Gridspeed Opens Subsidiary Operation in North America 3Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 2Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group 3
(Date:8/28/2014)... news release is available in German . ... water fish, owes its name to a striking pattern of ... types, black cells, reflective silvery cells, and yellow cells emerge ... and arrange as a multilayered mosaic to compose the characteristic ... three cell types have to interact to form proper stripes, ...
(Date:8/28/2014)... 28, 2014) Researchers at the University of Minnesota ... dystrophy (FSHD) to be used for muscle regeneration research ... therapies for FSHD. , The research is published in ... . , There is no treatment for FSHD, which ... type of muscular dystrophy. FSHD is an unusual genetic ...
(Date:8/28/2014)...  Privacy Advocate and Senior Staff Attorney at the ... the lineup of biometric and mobile commerce experts set ... Summit in Tampa, Florida on ... include Steven Rahman, Director, Technology and Strategy at Samsung, and ... theme of this year,s event is Mobility at the ...
Breaking Biology News(10 mins):How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3UMN researchers find animal model for understudied type of muscular dystrophy 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... that climate affects our water supply, but new research ... managers an unprecedented level of detail on how climate ... the Southeast. Researchers found that the groundwater, primarily ... directly influenced by the amount of precipitation that fell ...
... PhD, has won the Louis N. and Arnold M. ... the American Heart Association (AHA), marking the first time ... researcher has been the recipient. Dr. Qian ... and independent biomedical-research organization -- and a California Institute ...
... Cancer Discovery , a journal of the American Association ... be on the horizon for neuroendocrine prostate cancers, the ... M.D., professor of pathology and laboratory medicine at Weill ... of men with prostate cancer present with neuroendocrine prostate ...
Cached Biology News:Gladstone scientist receives American Heart Association's Katz prize for cardiovascular research 2
... 6-Fam, Hex, Tet Cy3, Cy5, Texas ... Black Hole Quenchers Molecular Beacons* ... Joe 3 Dabcyl Dabcyl*Licensed from ... Double labelled probes are purified either by ...
... a high performance spectral scanning multimode ... With the advanced SkanIt Software it ... drug discovery assay development. Varioskan provides ... time-resolved fluorescence and photometric assays and ...
Roll of Mesh 5m x 25cm...
... Innovative HL-2000 HybriLinker combines the benefits of ... one self-contained, space saving unit. , ... Science Laboratory allows crosslinking ,and hybridization at one ... the HL-2000 operate independently of each other ...
Biology Products: